

FINDING OF NO SIGNIFICANT IMPACT

Marketing Orders for

Ashton Senioritas Bx50 and Ashton Connecticut Senioritas Bx50

Marketed by Ashton Distributors Inc.

The Center for Tobacco Products of the Food and Drug Administration (FDA) has carefully considered the potential environmental impacts of these actions and has concluded that these actions will not have significant effects on the quality of the human environment. Therefore, environmental impact statements are not required.

Ashton Distributors Inc. wishes to introduce 2 leaf-wrapped cigar products into interstate commerce for commercial distribution in the United States and submitted to FDA substantial equivalence reports to obtain marketing orders under the provisions of Sections 905(j) and 910 of the Federal Food, Drug, and Cosmetic Act.

The Agency prepared the Programmatic Environmental Assessment (PEA), dated December 20, 2021, in accordance with the Council on Environmental Quality's regulations (40 CFR Part 1500–1508) implementing the National Environmental Policy Act (NEPA) and FDA's NEPA regulations (21 CFR 25.40) to support the findings of no significant impact. The evidence supporting these findings is contained in the attached PEA, which is available to the public upon request.

The PEA evaluates potential environmental effects due to manufacturing, use, and disposal of the new products including air quality, water resources, soil, land use, zoning, biological resources, socioeconomics, environmental justice, solid waste hazardous materials, floodplains, wetlands, and costal zones. No increased or new types of environmental impacts due to manufacturing are anticipated. The Agency does not foresee that use of the new products would result in new or different environmental impacts. The Agency believes that the disposal of the new products is the same as the disposal conditions of other leaf-wrapped cigar products that are currently marketed in the United States. Therefore, the Agency does not foresee adverse impacts to the environment due to the proposed actions as a result of manufacturing, use, and disposal of the new products.

Digitally signed by Luis G. Valerio -S

Date: 2021.12.21 09:59:46 -05'00'

Approved by

Luis G. Valerio, Jr., Ph.D., ATS
Associate Director
Division of Nonclinical Science
Office of Science
Center for Tobacco Products
U.S. Food and Drug Administration